


This listing of claims will replace all prior versions of claims in the application.

Listing of Claims: Please amend the claims as follows:

We claim:

Claim 1. (Currently Amended) A compound of the formula I



in which wherein

R¹ is H, A or SO₂A,

A is straight-chain or branched alkyl having from 1 to 10 carbon atoms, alkenyl having from 2 to 10 carbon atoms or alkoxyalkyl having from 2 to 10 carbon atoms, and

D-E is R²C=CR⁴ or R²R³C-CR⁴R⁵,

in which wherein

R², R³, R⁴ and R⁵ are selected, independently, from

A, cycloalkyl having from 3 to 7 carbon atoms, Hal, CH₂Hal, CH(Hal)₂, C(Hal)₃, NO₂, (CH₂)_nCN, (CH₂)_nN(R⁶)₂, (CH₂)_nN(R⁶)Ar, (CH₂)_nN(R⁶)Het, (CH₂)_nN(Ar)₂, (CH₂)_nN(Het)₂, (CH₂)_nCOOR⁶, (CH₂)_nCOOAr, (CH₂)_nCOOHet, (CH₂)_nCON(R⁶)₂, (CH₂)_nCON(R⁶)Ar, (CH₂)_nCON(R⁶)Het, (CH₂)_nCON(Ar)₂, (CH₂)_nCON(Het)₂, (CH₂)_nNR⁶COR⁶, (CH₂)_nNR⁶CON(R⁶)₂, (CH₂)_nNR⁶SO₂A, (CH₂)_nSO₂N(R⁶)₂, (CH₂)_nSO₂NR⁶(CH₂)_mAr, (CH₂)_nSO₂NR⁶(CH₂)_mHet, (CH₂)_nS(O)_wR⁶, (CH₂)_nS(O)_wAr, (CH₂)_nS(O)_wHet, (CH₂)_nOOCR⁶, (CH₂)_nHet, (CH₂)_nAr,

$(CH_2)_nCOR^6$, $(CH_2)_nCO(CH_2)_mAr$, $(CH_2)_nCO(CH_2)_mHet$,
 $(CH_2)_nCOO(CH_2)_mAr$, $(CH_2)_nCOO(CH_2)_mHet$, $(CH_2)_nOR^6$,
 $(CH_2)_nO(CH_2)_mAr$, $(CH_2)_nO(CH_2)_mHet$, $(CH_2)_nSR^6$,
 $(CH_2)_nS(CH_2)_mAr$, $(CH_2)_nS(CH_2)_mHet$, $(CH_2)_nN(R^6)(CH_2)_mAr$,
 $(CH_2)_nN(R^6)(CH_2)_mHet$, $(CH_2)_nSO_2N(R^6)(CH_2)_mAr$,
 $(CH_2)_nN(R^6)SO_2(CH_2)_mAr$, $(CH_2)_nSO_2N(R^6)(CH_2)_mHet$,
 $(CH_2)_nN(R^6)SO_2(CH_2)_mHet$, $(CH_2)_nCON(R^6)(CH_2)_mAr$,
 $(CH_2)_nN(R^6)CO(CH_2)_mAr$, $(CH_2)_nCON(R^6)(CH_2)_mHet$,
 $(CH_2)_nN(R^6)CO(CH_2)_mHet$, $CH=N-OA$, $CH_2CH=N-OA$,
 $(CH_2)_nNHOA$, $(CH_2)_nCH=N-Het$, $(CH_2)_nOCOR^6$,
 $(CH_2)_nOC(O)N(R^6)_2$, $(CH_2)_nOC(O)NR^6(CH_2)_mAr$,
 $(CH_2)_nOC(O)NR^6(CH_2)_mHet$, $(CH_2)_nNR^6COOR^6$,
 $(CH_2)_nNR^6COO(CH_2)_mAr$, $(CH_2)_nNR^6COO(CH_2)_mHet$,
 $(CH_2)_nN(R^6)CH_2CH_2OR^6$, $(CH_2)_nN(R^6)CH_2CH_2OCF_3$,
 $(CH_2)_nN(R^6)C(R^6)HCOOR^6$, $(CH_2)_nN(R^6)CH_2COHet$,
 $(CH_2)_nN(R^6)CH_2Het$, $(CH_2)_nN(R^6)CH_2CH_2N(R^6)CH_2COOR^6$,
 $(CH_2)_nN(R^6)CH_2CH_2N(R^6)_2$, $CH=CHCOOR^6$,
 $CH=CHCH_2NR^6Het$, $CH=CHCH_2N(R^6)_2$, $CH=CHCH_2OR^6$,
 $(CH_2)_nN(COOR^6)COOR^6$, $(CH_2)_nN(CONH_2)COOR^6$,
 $(CH_2)_nN(CONH_2)CONH_2$, $(CH_2)_nN(CH_2COOR^6)COOR^6$,
 $(CH_2)_nN(CH_2CONH_2)COOR^6$, $(CH_2)_nN(CH_2CONH_2)CONH_2$,
 $(CH_2)_nCHR^6COR^6$, $(CH_2)_nCHR^6COOR^6$, $(CH_2)_nCHR^6CH_2OR^6$,
 $(CH_2)_nOCN$ or $(CH_2)_nNCO$,

in which wherein

R^6 is selected, independently, from H, A or cycloalkyl having from 3 to 7 carbon atoms,

Het is a saturated, unsaturated or aromatic mono- or bicyclic heterocyclic radical which is unsubstituted or mono- or poly-substituted by A, Hal, NO_2 , CN, OR^6 , $N(R^6)_2$, $COOR^6$, $CON(R^6)_2$, NR^6COR^6 , $NR^6CON(R^6)_2$, NR^6SO_2A , COR^6 , $SO_2N(R^6)_2$, $S(O)_wA$ and/or $OOCR^6$,

Ar is an aromatic hydrocarbon radical having from 6 to 14 carbon atoms which is unsubstituted or mono- or polysubstituted by A, Hal, NO₂, CN, OR⁶, N(R⁶)₂, COOR⁶, CON(R⁶)₂, NR⁶COR⁶, NR⁶CON(R⁶)₂, NR⁶SO₂A, COR⁶, SO₂N(R⁶)₂, S(O)_wA and/or OOCR⁶,

w is 0, 1, 2 or 3, and

n and m, independently of one another, are 0, 1, 2, 3, 4 or 5;

X¹ is (CHR⁷)_g or (CHR⁷)_h-Q-(CHR⁸)_k, ~~in which~~ wherein

Q is ~~selected from~~ O, S, N-R⁶, (O-CHR⁷)_g, (CHR⁷-O)_g, CR⁹=CR¹⁰, (O-CHR⁹CHR¹⁰)_g, (CHR⁹CHR¹⁰-O)_g, C=O, C=S, C=NR⁶, CH(OR⁶), C(OR⁶)(OR⁶), C(=O)O, OC(=O), OC(=O)O, C(=O)N(R⁶), N(R⁶)C(=O), C(=S)N(R⁶), N(R⁶)C(=S), OC(=O)N(R⁶), N(R⁶)C(=O)O, CH=N-O, CH=N-NR⁶, OC(O)NR⁶, NR⁶C(O)O, S=O, SO₂, SO₂NR⁶ ~~and~~ or NR⁶SO₂,

g is 1, 2, 3, 4, 5 or 6,

h and k, independently of one another, are 0, 1, 2, 3, 4, 5 or 6,

and

R⁷, R⁸, R⁹, R¹⁰ and R¹², independently of one another, are as defined for R² to R⁵;

p is 0, 1, 2 or 3,

E is H, A, (CH₂)_nHet, (CH₂)_nAr or cycloalkyl having from 3 to 7 carbon atoms,

G is an optionally substituted alkylene radical having from 1 to 4 carbon atoms, where the substituents are selected from the meanings indicated for R⁴,

or

E and G, together with the N atom to which they are bonded, are an unsubstituted or substituted 5-, 6- or 7-membered, mono- or bicyclic heterocyclic radical, which may have 1, 2 or 3 further heteroatoms selected from N, O and S,

X² is a bond or is selected, independently, from the meanings indicated for X¹,

Z is H or is a saturated, mono- or polyethylenically unsaturated or aromatic carbocyclic radical having from 5 to 10 carbon atoms or a saturated, mono- or polyethylenically unsaturated or aromatic heterocyclic radical having from 4 to 9 carbon atoms, where the carbocyclic or heterocyclic radical may be mono- or polysubstituted, where the substituents are selected, independently of one another, ~~from~~ comprise the meanings of R² to R⁵ other than H, and wherein the heterocyclic radical contains from 1 to 4 heteroatoms which is selected, independently of one another, ~~from~~ N, O and or S,

and

Hal is F, Cl, Br or I,

or a pharmaceutically acceptable salt, solvate, stereoisomer or mixture thereof.

Claim 2. (Currently Amended)
Claim 1, in which wherein

The compound of the formula I according to

A is straight-chain alkyl having from 1 to 4 carbon atoms or branched alkyl having from 3 to 6 carbon atoms, and

D-E is $R^2C=CR^4$ or $R^2R^3C-CR^4R^5$,
 in which R^2 , R^3 and R^5 are selected, independently, from A and
 cycloalkyl having from 3 to 7 carbon atoms,
 and

R^4 is Hal, CH_2Hal , $CH(Hal)_2$, $C(Hal)_3$, NO_2 , $(CH_2)_nCN$,
 $(CH_2)_nCOOR^6$, $(CH_2)_nCON(R^6)_2$, $(CH_2)_nNR^6COR^6$,
 $(CH_2)_nNR^6CON(R^6)_2$, $(CH_2)_nNR^6SO_2A$, $(CH_2)_nSO_2N(R^6)_2$,
 $(CH_2)_nS(O)_wA$, $(CH_2)_nOOCR^6$, $(CH_2)_nCOR^6$, $(CH_2)_nCO(CH_2)_mAr$,
 $(CH_2)_nCO(CH_2)_mHet$, $(CH_2)_nCOO(CH_2)_mAr$,
 $(CH_2)_nCOO(CH_2)_mHet$, $(CH_2)_nOR^6$, $(CH_2)_nO(CH_2)_mAr$,
 $(CH_2)_nO(CH_2)_mHet$, $(CH_2)_nSR^6$, $(CH_2)_nS(CH_2)_mAr$,
 $(CH_2)_nS(CH_2)_mHet$, $(CH_2)_nN(R^6)(CH_2)_mAr$,
 $(CH_2)_nN(R^6)(CH_2)_mHet$, $(CH_2)_nSO_2N(R^6)(CH_2)_mAr$,
 $(CH_2)_nN(R^6)SO_2(CH_2)_mAr$, $(CH_2)_nSO_2N(R^6)(CH_2)_mHet$,
 $(CH_2)_nN(R^6)SO_2(CH_2)_mHet$, $(CH_2)_nCON(R^6)(CH_2)_mAr$,
 $(CH_2)_nN(R^6)CO(CH_2)_mAr$, $(CH_2)_nCON(R^6)(CH_2)_mHet$,
 $(CH_2)_nN(R^6)CO(CH_2)_mHet$, $(CH_2)_nN(R^6)_2$, $(CH_2)_nOCOR^6$,
 $(CH_2)_nOC(O)N(R^6)_2$, $(CH_2)_nOC(O)NR^6(CH_2)_mAr$,
 $(CH_2)_nOC(O)NR^6(CH_2)_mHet$, $(CH_2)_nNR^6COOR^6$,
 $(CH_2)_nNR^6COO(CH_2)_mAr$, $(CH_2)_nNR^6COO(CH_2)_mHet$,
 $(CH_2)_nN(R^6)CH_2CH_2OR^6$, $(CH_2)_nN(R^6)CH_2CH_2OCF_3$,
 $(CH_2)_nN(R^6)C(R^6)HCOOR^6$, $(CH_2)_nN(R^6)CH_2COHet$,
 $(CH_2)_nN(R^6)CH_2Het$, $(CH_2)_nN(R^6)CH_2CH_2N(R^6)CH_2COOR^6$,
 $(CH_2)_nN(R^6)CH_2CH_2N(R^6)_2$, $CH=CHCOOR^6$,
 $(CH_2)_nN(COOR^6)COOR^6$, $(CH_2)_nN(CONH_2)COOR^6$,
 $(CH_2)_nN(CONH_2)CONH_2$, $(CH_2)_nN(CH_2COOR^6)COOR^6$,
 $(CH_2)_nN(CH_2CONH_2)COOR^6$, $(CH_2)_nN(CH_2CONH_2)CONH_2$,
 $(CH_2)_nCHR^6COR^6$, $(CH_2)_nCHR^6COOR^6$ or $(CH_2)_nCHR^6CH_2OR^6$,

m is 0, 1, 2, 3, 4 or 5 and

n 0 or 1;

X^1 is $(CHR^7)_g$ or $Q-(CHR^8)_k$, in which

Q is selected from O, S, $N-R^6$, $(O-CHR^7)_g$, $(CHR^7-O)_g$, $CR^9=CR^{10}$, $(O-CHR^9CHR^{10})_g$, $(CHR^9CHR^{10}-O)_g$, C=O, C=S, $C=NR^6$, $C(OR^6)(OR^6)$, $C(=O)O$, $OC(=O)$, $OC(=O)O$, $C(=O)N(R^6)$, $N(R^6)C(=O)$, $OC(=O)N(R^6)$, $N(R^6)C(=O)O$, $CH=N-O$, $CH=N-NR^6$, $OC(O)NR^6$, $NR^6C(O)O$, S=O, SO_2 , SO_2NR^6 and NR^6SO_2 ,

g is 2, 3 or 4,

k is 1, 2 or 3, and

R^7 , R^8 , R^9 and R^{10} are selected, independently, from the meanings indicated for R^2 to R^5 ;

X^2 is a bond or independently is $(CHR^7)_g$ or $Q-(CHR^8)_k$, in which

Q is selected from O, S, $N-R^6$, $(O-CHR^7)_g$, $(CHR^7-O)_g$, $(O-CHR^9CHR^{10})_g$, $(CHR^9CHR^{10}-O)_g$, C=O, $CH(OR^6)$, $C(=O)O$, $OC(=O)$, $C(=O)N(R^6)$, $N(R^6)C(=O)$, S=O, SO_2 , SO_2NR^6 and NR^6SO_2 , where


g in X^2 is preferably 1 or 2 and k in X^2 is preferably 0 or 1, and

R^{12} is selected, independently, from the meanings of R^4 other than H,

or a pharmaceutically acceptable salt, solvate, stereoisomer or mixture thereof.

Claim 3. (Currently Amended)
from compounds of the formula Ia,

The compound according to Claim 1, selected



in-which wherein

R^1 , D-E and Z are as defined above, and in-which wherein

X^1 is $(CHR^7)_g$ or $(CHR^7)_h-Q-(CHR^8)_k$, in-which wherein

Q is ~~selected from~~ O, S, $N-R^6$, $(O-CHR^7)_g$, $(CHR^7-O)_g$, $CR^9=CR^{10}$, $(O-CHR^9CHR^{10})_g$, $(CHR^9CHR^{10}-O)_g$, C=O, C=S, $C=NR^6$, $CH(OR^6)$, $C(OR^6)(OR^6)$, $C(=O)O$, $OC(=O)$, $OC(=O)O$, $C(=O)N(R^6)$, $N(R^6)C(=O)$, $OC(=O)N(R^6)$, $N(R^6)C(=O)O$, $CH=N-O$, $CH=N-NR^6$, $OC(O)NR^6$, $NR^6C(O)O$, S=O, SO_2 , SO_2NR^6 and or NR^6SO_2 ,

g is 1, 2, 3, 4, 5 or 6,

h and k, independently of one another, are 0, 1, 2, 3, 4, 5 or 6, and

R^6 is selected, independently, from H, A or cycloalkyl having from 3 to 7 carbon atoms,

R^7 , R^8 , R^9 and R^{10} are selected, independently, from the meanings indicated for R^2 to R^5 ;

Y is CH, N, COR^{11} , CSR^{11} , an unsubstituted or substituted, spiro-linked carbocyclic radical having from 5 to 7 carbon atoms or an unsubstituted or substituted, spiro-linked, 5-, 6- or 7-membered heterocyclic radical having from 1 to 3 heteroatoms selected from N, S or O,

R^{11} is H, A, $(CH_2)_n$ Het, $(CH_2)_n$ Ar or cycloalkyl having from 3 to 7 carbon atoms,

X^2 is a bond or O, S, $N-R^7$, CH_2 or CH_2CH_2 ,

p, q and r, independently of one another, are 0, 1, 2 or 3

and

Hal is F, Cl, Br or I, and

R^{12} and R^{13} , independently of one another, Hal, CN , NO_2 , OR^6 , $N(R^6)_2$, NO_2 , CN , $COOR^6$, $CON(R^6)_2$, NR^6COR^6 , $NR^6CON(R^6)_2$, NR^6SO_2A , COR^6 , SO_2NR^6 , $S(O)_wA$, $OOOR^6$ and/or $C(NH)NOH$,

or a pharmaceutically acceptable salt, solvate, stereoisomer or mixture thereof.

Claim 4. (Currently Amended) A compound of the formula which is

- a) 6-{3-[4-(4-fluorobenzyl)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;
- b) 6-{3-[4-(2,4-difluorobenzyl)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;
- c) 6-{3-[4-(4-fluorophenoxy)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;
- d) 4-{3-[4-(4-fluorobenzyl)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;
- e) 4-{3-[4-(2,4-difluorobenzyl)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;
- f) 4-{3-[4-(4-fluorophenoxy)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;
- g) 5-{3-[4-(4-fluorophenoxy)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;
- h) 5-{3-[4-(4-fluorobenzyl)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;

- i) 5-{3-[4-(2,4-difluorobenzyl)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;
- j) 5-{3-[4-(4-cyanophenyl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;
- k) 5-{4-[3-(3-cyano-1H-indol-6-yl)propyl]piperazin-1-yl}benzofuran-2-carboxamide;
- l) 5-{3-[4-(2-oxo-2H-chromen-6-yl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;
- m) 5-{4-[3-(3-cyano-1H-indol-4-yl)propyl]piperazin-1-yl}-benzofuran-2-carboxamide;
- n) 5-{4-[3-(3-cyano-1H-indol-5-yl)propyl]piperazin-1-yl}-benzofuran-2-carboxamide;
- o) 5-{3-[4-(1H-indol-4-yl)-piperazin-1-yl]propyl}-1-methanesulfonyl-1H-indole-3-carbonitrile;
- p) 5-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]-1H-indole-3-carbonitrile;
- q) 5-[3-(4-benzo[1,2,5]thiadiazol-4-yl)piperazin-1-yl]propyl]-1H-indole-3-carbonitrile;
- r) 3-{1-[3-(3-cyano-1H-indol-5-yl)propyl]piperidin-4-yl}-1H-indole-5-carboxamide;
- s) 5-[3-(4-quinolin-8-yl)piperazin-1-yl]propyl]-1H-indole-3-carbonitrile;
- t) 5-{3-[4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;
- u) 1-methanesulfonyl-5-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]-1H-indole-3-carbonitrile;
- v) 5-{3-[4-(1H-indol-4-yl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;
- w) 5-{3-[4-(1H-indol-3-yl)piperidin-1-yl]propyl}-1H-indole-3-carbonitrile;
- x) 5-{3-[4-(5-fluoro-1H-indol-3-yl)piperidin-1-yl]propyl}-1H-indole-3-carbonitrile;
- y) 3-{1-[3-(3-cyano-1H-indol-5-yl)propyl]piperidin-4-yl}-1H-indole-5-carbonitrile;


- z) 5-{3-[4-(6-fluoro-1H-indol-3-yl)piperidin-1-yl]propyl}-1H-indole-3-carbonitrile;
- aa) 5-{3-[4-(4-fluoro-1H-indol-3-yl)piperidin-1-yl]propyl}-1H-indole-3-carbonitrile;
- bb) 5-[3-(4-benzo[d]isothiazol-3-ylpiperazin-1-yl)propyl]-1H-indole-3-carbonitrile;
- cc) 4-{1-[3-(3-cyano-1H-indol-6-yl)propyl]piperidin-4-yloxy}benzamide;
- dd) 6-{3-[4-(2-cyano-3-methoxyphenyl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;
- ee) 6-{3-[4-(4-cyano-3-methoxyphenyl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;
- ff) 6-{3-[4-(4-cyano-2-methoxyphenyl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;
- gg) 4-[3-(4-pyrazol-1-ylmethyl-1-piperidyl)propyl]-1H-indole-3-carbonitrile;
- hh) N-(6-{4-[3-(3-cyano-1H-indol-5-yl)propyl]piperazin-1-yl}-2-oxo-2H-chromen-3-yl)acetamide;
- ii) 5-{3-[(pyridin-3-ylmethyl)amino]propyl}-1H-indole-3-carbonitrile;
- jj) 5-{3-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;
- kk) 5-[3-(4-pyrimidin-2-ylpiperazin-1-yl)propyl]-1H-indole-3-carbonitrile;
- ll) 5-{3-[(2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl)amino]propyl}-1H-indole-3-carbonitrile;
- mm) 5-{3-[4-(3-methoxyphenyl)-3-methylpiperazin-1-yl]propyl}-1H-indole-3-carbonitrile;
- nn) 5-{3-[4-(1-methyl-1H-imidazo[4,5-c]pyridin-4-yl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;
- oo) N-(4-{1-[3-(3-cyano-1H-indol-5-yl)propyl]piperidin-4-ylmethyl}phenyl)acetamide;
- pp) 5-{3-[4-(4-pyridin-3-ylthiazol-2-yl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;
- qq) ethyl 2-{4-[3-(3-cyano-1H-indol-5-yl)propyl]piperazin-1-yl}-thiazole-

- 4-carboxylate;
- rr) 5-{3-[3-(2-oxopyrrolidin-1-yl)propylamino]propyl}-1H-indole-3-carbonitrile;
- ss) ethyl (6-{4-[3-(3-cyano-1H-indol-5-yl)propyl]piperazin-1-yl}-2-oxo-2H-chromen-3-yl)carbamate;
- tt) 5-{3-[4-(3-amino-2-oxo-2H-chromen-6-yl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;
- uu) methyl (6-{4-[3-(3-cyano-1H-indol-5-yl)propyl]piperazin-1-yl}-2-oxo-2H-chromen-3-yl)carbamate;
- vv) 2-{4-[3-(3-cyano-1H-indol-5-yl)propyl]-piperazin-1-yl}thiazole-4-carboxamide; or
- ww) 4-[3-(3-cyano-1H-indol-5-yl)propyl]piperazine-1-thiocarboxamide;

or a pharmaceutically acceptable salt, solvate, stereoisomer or mixture thereof.

Claim 5. (Currently Amended) A process for the preparation of a compound of formula I according to Claim 1 or a salt thereof comprising reacting


- a) a compound of the formula II



~~in which~~ wherein

L¹ is Cl, Br, I, OH, a reactively esterified OH group or a diazonium group, and R¹, D, E, R¹², p and X¹ are as defined in Claim 1,

- b) with a compound of the formula III



III

~~in which~~ wherein

L^2 is H or a metal ion, and E, G, X^2 and Z are as defined in Claim 1,

and optionally

- c) converting the resultant compound of the formula I into a salt by treatment with an acid.

Claim 6. (Previously Presented) A process for the preparation of a pharmaceutical composition, comprising converting a compound of Claim 1 into a suitable dosage form together with at least one solid, liquid or semi-liquid excipient or adjuvant.

Claim 7. (Previously Presented) A pharmaceutical composition comprising at least one compound of Claim 1 and a pharmaceutically acceptable carrier.

Claim 8. (Cancelled)

Claim 9. (Currently Amended) A method for ~~modulating~~ inhibiting the activity of an excitatory amino acid in a cell, comprising contacting said cell with a compound of claim 1.

Claim 10. (Currently Amended) A method for ~~modulating~~ inhibiting the activity of a glycine transporter comprising contacting said transporter with a compound of claim 1.

Claim 11. (Cancelled)

Claim 12. (Currently Amended) A method for ~~preventing or~~ treating a 5HT-

mediated disease comprising administering to a host in need thereof a compound of claim 1.

Claim 13. (Currently Amended) A method according to Claim 12, wherein said disease is ~~selected from the group comprising~~ depression, strokes, cerebral ischaemia, extrapyramidal motor side effects of neuroleptics and of Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, brain and spinal cord trauma, obsessive-compulsive disorder, sleeping disorders, tardive dyskinesia, learning disorders, age-related memory disorders, eating disorders, and/or sexual dysfunctions.


Claim 14. (Currently Amended) A method for treating ~~and/or preventing~~ schizophrenia, depression, dementia, Parkinson's disease, Alzheimer's disease, Lewy bodies dementia, Huntington's disease, Tourette's syndrome, anxiety, learning and memory impairments, neurodegenerative diseases, cognitive impairments, nicotine dependence or pain comprising administering to a host in need thereof a compound of claim 1.

Claim 15. (Previously Presented) A method for combating neurodegenerative diseases, cerebrovascular diseases, epilepsy, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, cerebral ischaemia, infarction or psychoses comprising administering to a host in need thereof a compound of claim 1.

Claim 16. (Previously Presented) A method for combating neurodegenerative diseases, cerebrovascular diseases, epilepsy, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, cerebral ischaemia, infarction or psychoses comprising administering to a host in need thereof a pharmaceutical composition of claim 7.

Claim 17. (Cancelled)


Claim 18. (Withdrawn, Currently Amended) A compound of the formula II



in which wherein

L^1 is Cl, Br, I, OH, a reactively esterified OH group or a diazonium group, and R^1 , D, E, R^{12} , p and X^1 are as defined in Claim 1.


Claim 19. (Withdrawn, Currently Amended) A compound of the formula III



in which wherein

L^2 is H or a metal ion, and E, G, X^2 and Z are as defined in Claim 1.

Claim 20. (Withdrawn, Currently Amended) A compound of the formula Ia



wherein

R^1 is H, A or SO_2A

A is straight-chain or branched alkyl having from 1 to 10 carbon atoms, alkenyl having from 2 to 10 carbon atoms or alkoxyalkyl having from 2 to 10 carbon atoms, and

D-E $R^2C=CR^4$, wherein R^2 is H or methyl and R^4 is CN

X^1 is $(CHR^7)_g$

g is 1, 2, 3, 4, 5 or 6,

R^7 is selected, independently, from the meanings indicated for R^2 to R^5 ;

Y is CH or N,


q is 0,


p and r are, independently of one another, 0, 1, 2 or 3

Hal is F, Cl, Br or I,

R^{12} and R^{13} , independently of one another, are selected from the meanings of R^4 other than H and are, independently of one another, Hal, CN, NO_2 , OR^6 , $N(R^6)_2$, NO_2 , CN, $COOR^6$, $CON(R^6)_2$, NR^6COR^6 , $NR^6CON(R^6)_2$, NR^6SO_2A , COR^6 , SO_2NR^6 , $S(O)_wA$, $OOCR^6$ and/or $C(NH)NOH$, and

X^2-Z is selected from the group consisting of





in which wherein

X^2 is a bond,

R^{14} is selected, independently, from Hal, A, $(CH_2)_nHet$, $(CH_2)_nAr$, $(CH_2)_nCOO(CH_2)_mAr$, $(CH_2)_nCOO(CH_2)_mHet$, $(CH_2)_nOR^6$, $(CH_2)_nO(CH_2)_mAr$, $(CH_2)_nO(CH_2)_mHet$, $(CH_2)_nN(R^6)(CH_2)_mAr$, $(CH_2)_nN(R^6)(CH_2)_mHet$, $(CH_2)_nSO_2N(R^6)(CH_2)_mAr$, $(CH_2)_nN(R^6)SO_2(CH_2)_mAr$, $(CH_2)_nSO_2N(R^6)(CH_2)_mHet$, $(CH_2)_nN(R^6)SO_2(CH_2)_mHet$, $(CH_2)_nN(R^6)_2$, $(CH_2)_nNHOA$, $(CH_2)_n(R^6)Het$, $(CH_2)_nOCOR^6$, $(CH_2)_nOC(O)N(R^6)_2$, $(CH_2)_nOC(O)NR^6(CH_2)_mAr$, $(CH_2)_nOC(O)NR^6(CH_2)_mHet$, $(CH_2)_nNR^6COOR^6$, $(CH_2)_nNR^6COO(CH_2)_mAr$, $(CH_2)_nNR^6COO(CH_2)_mHet$, or CN

w is 0, 1, 2 or 3,

t is 0, 1, 2, 3, 4 or 5, and

m is 0, 1, 2, 3, 4, or 5


n is 0, 1, 2, or 3

R' is H, A, (CH₂)_nHet, (CH₂)_nAr, cycloalkyl having from 3 to 7 carbon atoms or SO₂A;


or a pharmaceutically salt, solvate, stereoisomer, or mixture thereof.

Claim 21. (Previously Presented)


A compound of the formula IIa



wherein R¹ and R² are as defined in claim 20; and
Y-Z is a radical of the formulae




or a radical of the formulae



or a pharmaceutically salt, solvate, stereoisomer, or mixture thereof.

Claim 22. (Withdrawn, Currently Amended)
according to claim 20

A compound of the formula Ia



wherein

R^1 is H or A

A is straight-chain or branched alkyl having from 1 to 10 carbon atoms, alkenyl having from 2 to 10 carbon atoms or alkoxyalkyl having from 2 to 10 carbon atoms, and

D-E $R^2C=CR^4$, wherein R^2 is H or methyl and R^4 is CN

X^1 is $(CHR^7)_g$

g is 3,

R^7 is selected, independently, from the meanings indicated for R^2 to R^5 ;

Y is CH or N,


q is 0,


p and r are, independently of one another, 0, 1, 2 or 3

Hal is F, Cl, Br or I,

R^{12} and R^{13} , are, independently of one another, Hal, CN, NO_2 , OR^6 , $N(R^6)_2$, NO_2 , CN, $COOR^6$, $CON(R^6)_2$, NR^6COR^6 , $NR^6CON(R^6)_2$, NR^6SO_2A , COR^6 , SO_2NR^6 , $S(O)_wA$, $OOCR^6$ and/or $C(NH)NOH$, and

X^2-Z is selected from the group consisting of





in which wherein

X^2 is a bond,

R^{14} is selected, independently, from Hal, NO_2 , OR^6 , $N(R^6)_2$, CN, $COOR^6$, $CON(R^6)_2$, NR^6COR^6 , $NR^6CON(R^6)_2$, NR^6SO_2A , COR^6 , SO_2NR^6 , $S(O)_wA$, $OO CR^6$ and/or $C(NH)NOH$,

w is 0, 1, 2 or 3,

t is 1, 2, 3, and

R' is H, A, $(CH_2)_nHet$, $(CH_2)_nAr$, cycloalkyl having from 3 to 7 carbon atoms or SO_2A ;

or a pharmaceutically salt, solvate, stereoisomer, or mixture thereof.